Robert W. Leasure Jr.
Net Worth

Last updated:

What is Robert W. Leasure Jr. net worth?

The estimated net worth of Mr. Robert W. Leasure Jr. is at least $5,269,267 as of 17 Feb 2022. He owns shares worth $484,867 as insider and has received compensation worth at least $4,784,400 in Inotiv, Inc..

What is the salary of Robert W. Leasure Jr.?

Mr. Robert W. Leasure Jr. salary is $797,400 per year as Pres, Chief Executive Officer & Director in Inotiv, Inc..

How old is Robert W. Leasure Jr.?

Mr. Robert W. Leasure Jr. is 65 years old, born in 1960.

What stocks does Robert W. Leasure Jr. currently own?

As insider, Mr. Robert W. Leasure Jr. owns shares in one company:

Company Title Shares Price per share Total value
Inotiv, Inc. (NOTV) Pres, Chief Executive Officer & Director 285,216 $1.7 $484,867

What does Inotiv, Inc. do?

Inotiv, Inc. provides drug discovery and development services to the pharmaceutical, chemical, and medical device industries; and sells analytical instruments to the pharmaceutical development and contract research industries. It operates through two segments, Contract Research Services and Research Products. The Contract Research Services segment offers screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance, and quality control testing services. This segment provides analytical method development and validation; drug metabolism, bioanalysis, and pharmacokinetics testing to identify and measure drug and metabolite concentrations in complex biological matrices; in vivo sampling services for the continuous monitoring of chemical changes in life; stability testing to ensure the integrity of various solutions used in nonclinical and clinical studies, and post-study analyses; non-clinical toxicology and pathology services; and climate-controlled archiving services for its customers' data and samples. The Research Products segment designs, develops, manufactures, and markets in vivo sampling systems and accessories, including disposables, training, and systems qualification; physiology monitoring tools; liquid chromatography and electrochemistry instruments platforms; analytical products comprising liquid chromatographic and electrochemical instruments with associated accessories; and in vivo sampling products consisting of Culex family of automated in vivo sampling and dosing instruments. The company operates in the United States, rest of North America, the Pacific Rim, Europe, and internationally. It has an agreement with BioVaxys to conduct preclinical toxicity studies for its Covid-T Immunodiagnostic program. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was founded in 1974 and is headquartered in West Lafayette, Indiana.

NOTV logo
NOTV
Inotiv, Inc.
$1.7

Robert W. Leasure Jr. insider trading

Inotiv, Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Shares 5,000 $23.03 $115,130
Purchase
Common Shares 5,000 N/A N/A
Purchase
Common Shares 2,884 N/A N/A
Purchase
Common Shares 5,700 N/A N/A
Purchase
Common Shares 26,846 $3.72 $99,867
Purchase
Common Shares 11,500 N/A N/A
Purchase
Common Shares 16,000 $2.19 $35,040
Purchase
Common Shares 5,000 N/A N/A
Purchase
Common Shares 4 N/A N/A
Purchase
Common Shares 5,000 $1.96 $9,800
Purchase
Common Shares 1,000 $1.95 $1,950
Purchase
Common Shares 6,000 N/A N/A
Purchase
Common Shares 4,000 N/A N/A
Purchase
Common Shares 10,000 $1.62 $16,200
Purchase
Common Shares 8,900 $1.51 $13,439

Inotiv key executives

Inotiv, Inc. executives and other stock owners filed with the SEC:

  • Dr. John E. Sagartz D.V.M., DiplomateACVP, DVM, Ph.D. (60) Chief Strategy Officer & Director
  • Mr. Robert W. Leasure Jr. (65) Pres, Chief Executive Officer & Director
  • Ms. Beth A. Taylor CPA (60) Vice President of Fin. & Chief Financial Officer